KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Acadia Pharmaceuticals (ACAD) Other Gross PP&E Adjustments (2016 - 2026)

Acadia Pharmaceuticals has reported Other Gross PP&E Adjustments over the past 15 years, most recently at -$68.4 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments rose 18.22% year-over-year to -$68.4 million; the TTM value through Dec 2025 reached -$68.4 million, up 18.22%, while the annual FY2025 figure was -$68.4 million, 18.22% up from the prior year.
  • Other Gross PP&E Adjustments for Q4 2025 was -$68.4 million at Acadia Pharmaceuticals, up from -$79.5 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at -$64.6 million in Q2 2023 and troughed at -$95.2 million in Q4 2021.
  • A 5-year average of -$76.3 million and a median of -$76.2 million in 2024 define the central range for Other Gross PP&E Adjustments.
  • Biggest five-year swings in Other Gross PP&E Adjustments: tumbled 181.27% in 2021 and later grew 18.22% in 2025.
  • Year by year, Other Gross PP&E Adjustments stood at -$95.2 million in 2021, then increased by 2.2% to -$93.1 million in 2022, then grew by 4.73% to -$88.7 million in 2023, then grew by 5.79% to -$83.6 million in 2024, then increased by 18.22% to -$68.4 million in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for ACAD at -$68.4 million in Q4 2025, -$79.5 million in Q3 2025, and -$81.0 million in Q2 2025.